Definium's LSD drug DT120 hit its Phase 3 MDD primary endpoint, beating analyst expectations with significant improvement in depression symptoms.
Definium Therapeutics said its LSD candidate significantly improved depression symptoms in a Phase 3 study in major depressive disorder (MDD), with data exceeding analyst expectations.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal
LSD Just Passed Its Biggest Test Yet for Treating Depression
Definium LSD therapy helped patients with major depression in late-stage trial
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi
Biotech Goes Sky-High After LSD Drug Treats Depression
LSD's Depression Win; Summer Heat and Suicide; Antipsychotic Nonresponse Predictors
Psychedelic Stocks Could Explode Higher
What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
Definium Therapeutics, Inc. Announces Proposed Public Offering
DT120, a psychedelic that activates serotonin receptors, was generally well tolerated, with mostly mild side effects occurring on…
People taking Definium Therapeutics' DT120 showed long-lasting reductions in their depression symptoms compared to a placebo, the…
Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the…
Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating…
One analyst called this a "best-case" scenario for the company's experimental depression treatment.
News and commentary from the psychiatry world
